Skip to main content

$1.035 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
18 May 2025 at 5:57am
Register to track BD1 and receive email alerts.

Positive Results Evaluation of EXO-NET in Pancreatic Cancer

StockBot

416,823 posts

BD1 released this announcement to the ASX on 16 March 2021, 8:32. The announcement is marked as price sensitive, and is 3 page(s) in length and 195.45kb in size.

You can view all announcements from BD1 and see how they appear on a price chart on the announcements page.

At the date of this announcement, BD1 was 0.005% short sold according to ASIC data. It was ranked the 612th most shorted stock on the ASX. It is now ranked as the 513th most shorted stock on the ASX with 0.054% of total shares short sold as of the latest reported data (03 December 2021).

Other Recent Announcements from BD1
BARD1 Changes its Name to INOVIQ 8 December 2021, 8:58
Cleansing Notice - Issued of Four Shares - Resolution 5 AGM 7 December 2021, 12:12
Application for quotation of securities - BD1 7 December 2021, 12:06
Positive Results Evaluation of EXO-NET in Pancreatic Cancer 16 March 2021, 8:32
Appendix 2A 15 March 2021, 15:07
Australian Patent Granted for hTERT 15 March 2021, 8:30
BARD1 Achieves hTERT Registration and First Order in Korea 12 March 2021, 9:39
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track BD1 and receive email alerts.